Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
The USFDA has issued 5 observations pursuant to the completion of audit
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
FDA has concluded that this inspection is 'closed'
Subscribe To Our Newsletter & Stay Updated
